EFPIA disclosure code
The EFPIA Disclosure Code, adopted on 21 December 2013, requires that its Member Associations adopt transparency provisions into their own national codes. The EFPIA Disclosure Code establishes guidelines for EFPIA members to disclose certain transfers of value made to healthcare professionals and healthcare organizations. Examples of transactions disclosed include a grant to a healthcare organization (HCO) or a consultancy fee for a presentation or lecture by a health professional.
As a member company of EFPIA we fully support the EFPIA Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organizations and have begun disclosing payments to European-based healthcare professionals and health care organizations in 2016 in alignment with the disclosure code. We hope that it will serve to create a better understanding of, and ultimately build trust in, the validity of interactions with the medical profession.
What are the specifics of the EFPIA Disclosure Code?
- In accordance with the EFPIA Code as of 2019, BMS must collect, store, and disclose certain payments and transfers of value (TOV) made directly or indirectly to either HCPs or to HCOs. This has to be carried out in full compliance with local and European data protection laws and regulations where applicable.
- First disclosures were made in 2016 reflecting information about payments and TOV made in the 2015 calendar year.
- Disclosure of payments and TOV is required on an annual basis. BMS is committed to protecting Recipients personal data and will disclose payments and TOV made to Recipients only with their prior consent.
What payments and transfers of value will be disclosed relating to healthcare professionals and healthcare organizations?
| Healthcare Professional (HCP) | Healthcare Organization (HCO) |
|---|---|
|
|
Why the need for a Disclosure Code?
Increasingly, the public wants to know that relationships between the pharmaceutical industry, HCPs and HCOs do not inappropriately influence clinical decisions and that they can trust their HCP to recommend, administer or purchase appropriate care and treatments based only on clinical evidence and experience.
The hope is that the Code will help patients and other interested groups better understand the legitimate relationship between the pharmaceutical industry, HCPs and HCOs and that this will subsequently strengthen the working relationships.
For additional frequently asked questions on the EFPIA Disclosure Code
Please visit https://www.efpia.eu/media/580613/disclosure-qa.pdf
We collaborate with some of the country’s foremost medical experts, whose deep knowledge, expertise and insight within a specific disease area or therapeutic area to help ensure our medicines meet the needs of patients and helps patients prevail over serious diseases.
Guided by the highest ethical standards, including company policy and the PhRMA Code on Interactions with Health Care Professionals – we appropriately compensate physicians and clinical trial researchers for the time, expertise and services they provide to conduct industry-sponsored research or educate their peers about medicines, which advance clinical knowledge and ultimately benefit patients.
Please go to the search page and select BRISTOL MYERS SQUIBB
If you have a question about transactions reported by Bristol Myers Squibb, email your inquiries to: mg-transparency_bms@bms.com